Hardie D Grahame
Division of Molecular Physiology, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom.
Annu Rev Pharmacol Toxicol. 2007;47:185-210. doi: 10.1146/annurev.pharmtox.47.120505.105304.
The AMP-activated protein kinase (AMPK) system is a regulator of energy balance at both the cellular and whole-body levels that, once activated by low energy status, effects a switch from ATP-consuming anabolic pathways to ATP-producing catabolic pathways. It now appears to be the major target for two existing classes of drug used to treat type 2 diabetes, i.e., the biguanides and thiazolidinediones. However, in both cases these activate AMPK indirectly, and an interesting question concerns whether a drug that directly activated AMPK would retain the therapeutic benefits of the existing drugs while eliminating unwanted side effects. AMPK activators also now have potential as anticancer drugs.
AMP激活的蛋白激酶(AMPK)系统是细胞和全身水平能量平衡的调节因子,一旦被低能量状态激活,它会促使从消耗ATP的合成代谢途径转变为产生ATP的分解代谢途径。现在它似乎是用于治疗2型糖尿病的两类现有药物(即双胍类和噻唑烷二酮类)的主要靶点。然而,在这两种情况下,这些药物都是间接激活AMPK,一个有趣的问题是,直接激活AMPK的药物是否能在消除不良副作用的同时保留现有药物的治疗益处。AMPK激活剂现在也有作为抗癌药物的潜力。